Siegfried Holding AG
Siegfried's capital structure is relatively balanced, with a debt-to-equity ratio of 0.51, indicating moderate leverage. The company maintains a current ratio of 2.0, suggesting it has sufficient short-term liquidity to cover its obligations. However, its free cash flow of CHF 15.04 million is relatively low compared to its operating cash flow of CHF 228.16 million, indicating that capital expenditures are consuming a significant portion of its operating cash. In terms of profitability, Siegfried's return on equity (ROE) of 14.95% and return on assets (ROA) of 7.83% are strong, but they should be compared to the industry median to determine relative performance. The company's gross profit margin of 26.66% (CHF 353.99 million gross profit on CHF 1.33 billion revenue) is a key indicator of its pricing power and cost control. Siegfried's operating margin of 16.85% (CHF 223.76 million operating income) is also robust, but again, a comparison to industry peers is necessary to assess its competitive position. Geographically, Siegfried's revenue is concentrated in Europe, with no specific breakdown provided in the available data. The company's exposure to this region may present both opportunities and risks, particularly in light of regulatory changes and currency fluctuations. Siegfried operates in a single business segment, which simplifies its operations but also means that its performance is entirely dependent on the pharmaceuticals market. Looking ahead, Siegfried's growth trajectory is expected to be modest, with no specific numeric deltas provided for the current or next fiscal year. The company's capital expenditures of CHF 231.47 million are a significant outflow, which may impact its ability to reinvest in growth opportunities. Analysts have a generally positive outlook, with a mean recommendation of 2.10 (on a scale from 1 to 5) and a mean price target of CHF 104.00. Siegfried faces several risk factors, including liquidity concerns due to its negative net cash position after subtracting total debt. The company's liquidity risk is rated as medium, and while dilution risk is currently low, any future capital raising could change this. The company's reliance on a single business segment and geographic concentration in Europe also pose concentration risks. Recent events, such as the latest financial filings and analyst reports, indicate a stable but cautious outlook for Siegfried. The company's financial performance has been consistent, but there are no major new developments that would significantly alter its trajectory.
Business. Siegfried Holding AG is a Swiss pharmaceutical company that develops, produces, and markets generic and branded pharmaceutical products, primarily in the European market.
Classification. Siegfried is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.
- Siegfried maintains a strong ROE of 14.95% and ROA of 7.83%, indicating solid profitability.
- The company's debt-to-equity ratio of 0.51 suggests moderate leverage, but its negative net cash position raises liquidity concerns.
- Siegfried's free cash flow is low at CHF 15.04 million, with significant capital expenditures consuming a large portion of operating cash.
- Analysts have a generally positive outlook, with a mean recommendation of 2.10 and a mean price target of CHF 104.00.
- The company's geographic and business segment concentration presents both opportunities and risks.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.